Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study

In conclusion, the addition of a second long-acting bronchodilator in the real world setting treatment of COPD does not increase the risk of most cardiovascular events. The modest increase for heart failure may be due to residual confounding by indication and needs further investigation.

Source: European Respiratory Journal - November 7, 2016 Category: Respiratory Medicine Authors: Suissa, S., Dell'Aniello, S., Ernst, P. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research